Fertio, an international fertility care group and parent company of European Sperm Bank, announced that it has acquired Cascade Cryobank, a U.S.-based sperm bank founded in 2021. The deal marks Fertio’s expansion into the United States and reflects its strategy to build a global ecosystem of fertility care companies focused on transparency, innovation, and patient support.
Cascade Cryobank, based in Lynwood, Washington, is known for its Early Disclosure Program, which allows parents to access donor identity information immediately after a child’s birth. The acquisition brings together Fertio’s more than 20 years of global experience with Cascade’s approach to donor transparency, aiming to improve family-building options for parents in the U.S.
Following the transaction, Cascade Cryobank will continue to operate under its existing brand while benefiting from Fertio’s scale, donor management technology, and international expertise. The companies plan to collaborate on expanding services, enhancing donor programs, and setting new quality benchmarks in sperm donation and fertility care.
The partnership is built on shared values around high-quality care, ethical standards, and improving access to reproductive health services. Fertio said the acquisition supports its broader vision of creating a network of fertility companies that share best practices and innovate across markets to better support individuals and couples pursuing parenthood.
KEY QUOTES
“Welcoming Cascade Cryobank into the Fertio family is an important milestone. Their donor offering and innovative approach aligns strongly with our vision of rethinking fertility. Together, we see great potential to help more families conceive with donor transparency.”
David T. Hansen, CEO of Fertio
“For us, this is a chance to be part of something bigger. Joining Fertio gives us access to world-class donor management technology and the opportunity to set new standards in the fertility industry.”
Dr. John Carpenter, Founder of Cascade Cryobank
